Current Staging Strategies for Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Cell Carcinoma

Matthew Mossanen; Steven L Chang; Simon Kimm; Guru P Sonpavde; Adam S Kibel

doi:10.1016/j.ucl.2017.12.001

Current Staging Strategies for Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Cell Carcinoma

Urol Clin North Am. 2018 May;45(2):143-154. doi: 10.1016/j.ucl.2017.12.001.

Authors

Matthew Mossanen¹, Steven L Chang², Simon Kimm³, Guru P Sonpavde⁴, Adam S Kibel²

Affiliations

¹ Division of Urology, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, 45 Francis Street, Boston, MA 02111, USA. Electronic address: mmossanen@partners.org.
² Division of Urology, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, 45 Francis Street, Boston, MA 02111, USA.
³ Department of Surgery, Palo Alto Medical Foundation, 300 Pasteur Drive, Palo Alto, CA 94304, USA.
⁴ Department of Genitourinary Oncology, Dana Farber Cancer Institute (DFCI), 450 Brookline Avenue, Boston, MA 0221, USA.

PMID: 29650131
DOI: 10.1016/j.ucl.2017.12.001

Abstract

Please note, the synopsis was used from your supplied original manuscript, and not the accompanying abstract, per journal style: This article discusses current staging strategies in muscle-invasive bladder cancer and upper tract urothelial cell carcinoma. Current staging methods can help identify patients with localized or metastatic disease but are subject to limitations which must be considered.

Keywords: Imaging in bladder cancer; Muscle-invasive bladder cancer; Staging; Upper tract urothelial cell cancer.

Publication types

Review

MeSH terms

Carcinoma, Transitional Cell / pathology*
Humans
Kidney Neoplasms / pathology*
Lymphatic Metastasis
Neoplasm Staging / methods*
Prognosis
Ureteral Neoplasms / pathology*
Urinary Bladder Neoplasms / pathology*